Suzanne Ildstad - 22 Aug 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)

Role
Chief Scientific Officer
Signature
/s/ Mary Kay Fenton, attorney-in-fact
Issuer symbol
TRML
Transactions as of
22 Aug 2022
Net transactions value
-$1,470,000
Form type
4
Filing time
23 Aug 2022, 19:43:17 UTC
Previous filing
02 Feb 2022
Next filing
07 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TALS Common Stock Sale $1,470,000 -525,000 -15% $2.80 3,081,446 22 Aug 2022 Direct
holding TALS Common Stock 1,200,000 22 Aug 2022 By GRAT
holding TALS Common Stock 654,205 22 Aug 2022 See Footnote F1
holding TALS Common Stock 654,205 22 Aug 2022 See Footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held in a trust for the benefit of the Reporting Person's son. The Reporting Person's son is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2 These shares are held in a trust for the benefit of the Reporting Person's daughter. The Reporting Person's daughter is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.